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Abstract: P-Glycoprotein/MDR1 represents an important component of the blood brain barrier and contributes to multidrug  
resistance. We investigated two derivatives of the anti-malarial artemisinin, SM616 and GHP-AJM-3/23, concerning their ability to 
interact with P-glycoprotein. The ability of the two compounds to inhibit P-glycoprotein (P-gp) activity was examined in sensitive 
CCRF-CEM and P-gp over-expressing and multidrug-resistant CEM/ADR5000 cells as well as in porcine brain capillary endothelial
cells (PBCEC) by means of calcein-AM assays. Verapamil as well-known P-gp inhibitor was used as control drug. CEM/ADR5000 
cells exhibited cross-resistance to GHP-AJM-3/23, but slight collateral sensitivity to SM616. Furthermore, SM616 inhibited calcein 
efflux both in CEM/ADR5000 and PBCEC, whereas GHP-AJM-3/23 did only increase calcein fluorescence in PBCEC, but not 
CEM/ADR5000. This may be explained by the fact that CEM/ADR5000 only express P-gp but not other ATP-binding cassette 
transporters, whereas PBCEC are known to express several ABC transporters and calcein is transported by more than one ABC 
transporter. Hence, SM616 may be the more specific P-gp inhibitor. In conclusion, the collateral sensitivity of SM616 as well as the 
inhibition of calcein efflux in both CEM/ADR5000 cells and PBCEC indicate that this compound may be a promising P-gp  
inhibitor to treat cancer therapy and to overcome the blood brain barrier. 
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Introduction 
The medicinal herb, Artemisia annua L. (qinghao, Sweet 
Wormwood) is traditionally used in Chinese medicine against 
different ailments, such as fever, chills, nose bleeding, 
headache, jaundice, lupus erythematosus and hemorrhages. Its 
active principle is the 1,2,4-trioxane artemisinin, which was 
found to have anti-malarial activity in 1972.1 In the following 
years, several semisynthetic derivatives were developed to 
increase solubility in oil and water, i.e. artemether, arteether, 
artesunate. These substances are generally well-tolerated.2 
In the 1990s, artemisinin and its derivatives attracted the 
attention of cancer researchers as their anti-proliferative 
activity was discovered.3–8 Artesunate was shown to inhibit 
tumor cell growth by cell cycle arrest9–12 and apoptosis 
induction in tumor cells.7,13 Furthermore, it inhibits 
angiogenesis and metastasis in vitro and in vivo,14–17 and 
induces oxidative DNA damage.18,19 
The activity of artemisinin derivatives in malaria parasites is 
mainly based on the formation of reactive oxygen species 
(ROS) and carbon-centered radicals. While both damage 
different target proteins, ROS can also lead to lipid 
peroxidation. The activity against cancer cells seems to follow 
a similar pathway, as the over-expression of anti-oxidant genes 
decreases cytotoxicity of artesunate.9,20–22 Furthermore, iron (II) 
glycine sulfate (Ferrosanol®) and transferrin were shown to 
increase cytotoxicity of artesunate,23,24 pointing to a role of 
iron ions in a Fenton-type reaction of artemisinins. 
The epidermal growth factor receptor (EGFR) is linked to 
resistance against artesunate. Increased EGFR expression 
correlated with decreased artesunate toxicity in a COMPARE 
analysis of IC50 values of artesunate and genome-wide mRNA 
expression in the NCI cell line panel.9 Upon combination of 
artesunate with the EGFR tyrosine kinase inhibitor, erlotinib, 
supra-additive effects were observed in EGFR over-expressing 
cells.25 Furthermore, artesunate affects kinases of signalling 
pathways downstream of EGFR.26 Resistance to artesunate is 
also mediated by NF-κB.27 
A remarkable feature is that multidrug-resistant Plasmodium 
strains as well as multidrug-resistant cancer cells do not 
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exhibit cross-resistance to artesunate.9,28–30 The phenomenon 
of multidrug resistance is often caused by over-expression of 
ATP-binding cassette (ABC) transporters resulting in an 
increased efflux of their substrates.30–32 Over-expression of the 
ABC-transporter P-glycoprotein (P-gp)/MDR1 result in 
resistance to a wide variety of cancer drugs, e.g. 
anthracyclines, Vinca alkaloids, epipodophyllo-toxins, taxanes 
and others. P-gp is constitutively found in the blood-brain 
barrier, where it functions as an efflux pump to prevent 
xenobiotics from passing through the barrier. Artesunate was 
tested in several multidrug-resistant and drug-sensitive cell 
lines9,29,30 and no cross-resistance was observed. There is, 
however, not only a need for non-cross-resistant drugs, but 
also for inhibitors of P-gp function to improve standard 
chemotherapy of tumors and to overcome the blood brain 
barrier for pharmacological intervention in neurological 
diseases. 
In the present investigation, two new artemisinin derivatives 
have been tested, SM616 and GHP-AJM-3/23 in sensitive 
CCRF-/CEM and P-gp over-expressing and multidrug  
resistant CEM/ADR5000 leukemia cells as well as in porcine 
brain capillary endothelial cells (PBCEC). The capability of 
the artemisinin derivatives to modulate the efflux function of 
P-gp was measured by means of a calcein-AM assay.33 The 
results of the compounds were compared to the activity of 
verapamil, a well-described modulator of P-gp mediated efflux. 
 
Results and Discussion 
Growth Inhibition Assay. First, the cytotoxicity of the two 
artemisinin derivatives was determined in CCRF-CEM and 
CEM/ADR5000 leukemia cells. The IC50 values are shown in 
Table 1. The P-gp over-expressung and multidrug-resistant 
CEM/ADR5000 cells were 11.1-fold more resistant to GHP-
AJM-3/23 than the sensitive CCRF-CEM cells. The opposite 
was observed for SM616: CEM/ADR5000 cells were more 
sensitive to the compound than the parental CCRF-CEM cell 
line. The degree of resistance in CEM/ADR5000 cells was 
0.61. As a control, the response of the leukemia cells to doxo-
rubicin was investigated. CEM/ADR5000 cells revealed 4260-
fold resistance towards doxorubicin. 
 
Calcein-AM Assay with Adherent PBCEC. The efflux of 
calcein from PBCEC was measured to determine the effects of 
the two artemisinin derivatives on the activity of P-gp. Figure 
2 shows the averaged results of each two experiments. The 
intracellular calcein fluorescence considerable increased after 
treatment with GHP-AJM-3/23. A strong increase was 
observed within the first minutes of incubation. Although the 
intracellular accumulation slightly decreased afterwards, the 
level of untreated control cells was not reached (Figure 2a). 
The intracellular calcein fluorescence was stable upon 
application of SM616 and rather increased after 150 min, 
which speaks for an efficient inhibition of P-gp-mediated 
calcein efflux (Figure 2b). 
In each experiment, three different control measurements 
were carried out. (1) Krebs-Ringer-Buffer was added instead 
of calcein-AM to monitor the autofluorescence of PBCEC. 
The mean fluorescence value was subsequently subtracted 
from all other measured values. (2) The uptake and efflux of 
calcein as measured by adding Krebs-Ringer-Buffer instead of 
artemisinins. (3) As positive control, 25 μM Verapamil was 
used. Verapamil increased the cellular calcein fluorescence by 
550 to 600%. 
 
Calcein-AM Assay with CCRF-CEM and CEM/ADR5000
Leukemia Cells in Suspension. As a next step, the calcein 
fluorescence was studied in leukemia cell lines. The 
measurement of intracellular fluorescence was performed with 
flow cytometry, since the leukemia cells grew in suspension 
culture. Using forward sideward scatter, cell debris and cell 
doublettes were excluded. The suspensions were treated with 
propidium iodide to exclude dead cells from the measurement. 
Samples were measured and analyzed with the software 
CellQuest Pro. 
The flow cytometric histograms for the intracellular calcein 
fluorescence with and without treatment of cells with SM616 
are shown in Figure 3. SM616 had no effect in parental 
CCRF-CEM cells without P-gp expression (Figure 3a). In  
P-gp overexpressing CEM/ADR5000 cells, however, SM616 
caused a considerable dose-dependent increase of calcein  
fluorescence, indicating inhibition of P-gp-mediated efflux 
(Figure 3b). When the same experiment was performed with 
GHP-AJM-3/23, increased calcein fluorescence was not  
observed in CEM/ADR5000 cells, indicating that this  
compound was not able to block P-gp function (Figure 4). As 
a control drug, we used verapamil, which is a well-known  
P-hp inhibitor. The histograms in Figure 5 demonstrate, that a 
verapamil-induced increase of calcein fluorescence was  
measured in CEM/ADR5000 cells (Figure 5a), but not in 
CCRF-CEM cells (Figure 5b). 
Multidrug-resistant CEM/ADR5000 cells were cross-
resistant to GHP-AJM-3/23 but not SM616. P-glycoprotein is 
a broad spectrum transporter for a wide diversity of  
compounds. It is a characteristic feature of P-gp that it translo-
cates a wide variety of chemically diverse compounds. While 
many speculations on the mechanism of action of  
P-glycoprotein have been made, the only common property of 
P-glycoprotein substrates is their relative hydrophobic,  
amphiphilic nature.36,37 
Interestingly, CEM/ADR5000 cells did not reveal cross-
resistance to SM616. This phenomenon is described as  
‘collateral sensitivity’ and was first observed in the reaction of 
bacteria towards different antibiotics.38 It is also well-known 
in P-gp expressing and otherwise multidrug-resistant cells.39 
Rapid ATP-consumption by futile cycling, increased ROS 
production and glutathione depletion, altered lipophilicity of 
Table 1. 50% inhibition concentration (IC50) and relative degrees of resistance of two artemisinin derivatives and doxorubicin as 
control drug in human leukemic CCRF-CEM and CEM/ADR5000 cells determined by growth inhibition assay 
compound CCRF-CEM IC50 (µM) CEM/ADR5000 IC50 (µM) degree of resistance 
SM616 0.184 0.113 0.61 
GHP-AJM-3/23 0.0095 0.105 11.1 
Doxorubicin 0.0039 16.78 4260 
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cell membranes and other mechanisms were discussed as  
possible mechanisms to explain collateral sensitivity. The  
reasons are unknown yet, why CEM/ADR5000 cells exhibited 
collateral sensitivity towards SM616. 
Although both compounds are derivatives of artemisinin, 
they are structurally very different. GHP-AJM-3/23 is a dimer 
molecule of artemisinin, while SM616 is a monomer with an 
additional side chain. CEM/ADR5000 cells were cross-
resistant to one compound, but collateral sensitive to the other 
one. Furthermore, the calcein efflux was inhibited by SM616 
but not by GHP-AJM-3/23. These data may speak for different 
binding sites of the two compounds at P-gp. 
The binding of small molecules to P-gp is a matter of a long 
and inconclusive discussion. While initially one binding  
domain and subsequently two binding sites have been  
proposed for P-glycoprotein,40 more recent investigations  
suggested multiple different binding sites.41,42 An alternative 
model hypothesized that P-glycoprotein extrude diverse drugs 
by an induced-fit mechanism.43 Recently, homology models 
for P-glycoprotein based on the crystal structure of the bacterial
ABC transporter from Staphylococcus aureus Sav1866 have 
been described.44 Site-directed mutagenesis experiments fit to 
these putative binding sites of the homology models,45 but a 
final proof can only be delivered by drug-protein crystal  
structures. In own investigations, we also found an unexpected 
broad diversity of natural products, including several  
artemisinin derivatives as substrates or inhibitors of P-gp.46,16 
Considering this complex and unresolved situation, the  
substrate specificity of P-glycoprotein may be much broader 
than estimated thus far. 
Whereas SM616 inhibited calcein efflux both in 
CEM/ADR5000 cells in PBCEC, GHP-AJM-3/23(AR)  
inhibited calcein efflux in PBCEC but not in CEM/ADR5000 
cells. This result may be explained by the fact that other ABC-
 
Figure 2.  Inhibition of calcein efflux by (a) GHP-AJM-3/23 and (b) SM616 in PBCEC 
 
Figure 4.  Flow cytometric histograms of intracellular calcein 
fluorescence in (a) CCRF-CEM and (b) CEM/ADR5000 cells 
after treatment with various concentrations of GHP-AJM-
3/23(AR) 
 
Figure 5.  Flow cytometric histograms of intracellular calcein 
fluorescence in (a) CCRF-CEM and (b) CEM/ADR5000 cells 
after treatment with various concentrations of verapamil 
 
Figure 3.  Flow cytometric histograms of intracellular calcein 
fluorescence in (a) CCRF-CEM and (b) CEM/ADR5000 cells 
after treatment with various concentrations of SM616
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transporters in addition to P-gp are also expressed in 
PBCEC.47 MRP1 mRNA was found in cultured PBCEC,  
although to a 10-fold lower level than PGP mRNA. As calcein-
AM is also a substrate for MRP1,48 higher intracellular calcein 
content could be explained by interaction of GHP-AJM-
3/23(AR) with MRP1. By contrast, CEM/ADR5000 have been 
shown to express P-gp but not other ABC transporters.35 
In conclusion, two artemisinin derivatives, SM616 and 
GHP-AJM-3/23 showed different behavior in P-gp expressing 
cells. The missing cross-resistance of SM616 as well as the 
inhibition of calcein efflux in both CEM/ADR5000 cells and 
PBCEC indicate that this compound may be a promising P-gp 
inhibitor to treat cancer therapy and overcome the blood brain 
barrier. As artemisinins were generally well-tolerated in clinical
treatment against malaria in the past, SM616 might provide a 
non-toxic chemosensitizer. This hypothesis warrants more 
detailed investigations in the future. 
 
Experimental Section 
Drugs. The artemisinin derivative, SM616 ((16S)-cyano-(p-
bromo-phenyl)-methyl-12-deoxoartemisinyl ether), was syn-
thesized by Dr. Ying Li (Department of Synthetic Chemistry, 
Shanghai Institute of Materia Medica, Chinese Academy of 
Sciences, Shanghai, China). The compound is solid at room 
temperature and has a molecular weight of 478.38 g/mol. 
Stock solutions were prepared in DMSO. GHP-AJM-3/23 was 
synthesized by Dr. Gary H. Posner (Department of Chemistry, 
Johns Hopkins University, Baltimore MD, USA). It is an  
artemisinin-dimer molecule, which is solid at room tempera-
ture. The molecular weight is 838.96 g/mol. Stock solutions 
were prepared in DMSO. (±)-Verapamil hydrochloride was 
obtained from Sigma-Aldrich (Deisendorf, Germany) and  
calcein-acetoxymethylester (calcein-AM) was obtained from 
Invitrogen (Karlsruhe, Germany). 
 
Cells. The human leukemia cell lines CCRF-CEM and 
CEM/ADR5000 were obtained from Dr. Axel Sauerbrey  
(Department of Pediatrics, University of Jena, Germany). Cells 
were cultivated in RPMI 1640 medium, 2.0 g/L NaHCO3 with 
stable L-glutamine supplemented with 10% fetal calf serum 
and 0.1 U/ml/0.1 mg/ml Penicillin/Streptomycin (all Biochrom, 
Berlin, Germany) in a humidified 5% CO2 atmosphere at 
37 °C. CEM/ADR5000 cells were incubated in RPMI 1640 
medium containing 5000 ng/ml Doxorubicin for 24 h once a 
week. The CEM/ADR5000 line was developed by Kimmig et 
al. (1990).34 The cells express specifically P-gp/MDR1, but 
none of the other members of the ABC transporter family.35 
Porcine brain capillary endothelial cells (PBCEC) were  
isolated following a procedure previously described.33 Brains 
of freshly slaughtered animals were obtained from a local 
slaughterhouse and transported and stored in artificial cerebro-
spinal fluid (aCSF). The cortical grey matter was isolated by 
removing meninges, choroid plexus and blood vessels and 
minced to pieces of 1 to 2 mm³. The mass was then incubated 
in culture medium (1) containing 0.5% dispase II (Hoffmann 
LaRoche, Mannheim, Germany) for 2 h at 37 °C. The homog-
enate was centrifuged at 1000 × g for 10 min. After removing 
the supernatant, the pellet was suspended in culture medium 
containing 15% dextran (Sigma, Taufkirchen, Germany). In 
the following centrifugation at 5800 g for 10 min, the brain 
tissue was separated from the microvessels which form the 
pellet. Subsequently, the capillaries were incubated in culture 
medium containing 1 mg/mL collagenase-dispase (Hoffmann 
LaRoche, Mannheim, Germany) for 1.5 to 2 h. By filtration 
through a 150-μm Polymon® mesh (NeoLab Migge, Heidel-
berg, Germany) and another centrifugation step at 130 g for 10 
min, the cell suspension was further purified. Subsequently, 
cells were held in culture medium containing 10% horse  
serum. The suspension was then added to a discontinuous Per-
coll® (Pharmacia, Freiburg, Germany) gradient, consisting of 
Percoll® 1.03 g/mL and 1.07 g/mL at a ratio of 4 : 3. It is criti-
cal that the following centrifugation step at 1000 × g for 10 
min is performed without breaking to prevent an unwanted 
mixture of the two phases. While debris was collected in the 
low-density fraction and erythrocytes in the high-density  
fraction, the capillary endothelial cells remain at the interface, 
where they were collected. Two more centrifugation steps at 
130 × g at 10 min followed. The cells were then suspended in 
culture medium containing horse serum. Cells were seeded at a 
density of 250,000 cells/cm² in 96-well-plates and cultivated in 
a humidified 5% CO2 atmosphere at 37 °C. The culture  
medium was medium 199, supplemented with 0.8 mM L-
glutamine, penicillin/streptomycin (100 U/mL; 100 μg/mL), 
100 μg/mL kanamycin and 10 mM HEPES, pH 7.4 (all from 
Biochrom, Berlin, Germany). 
 
Growth Inhibition Assay. CEM-cells were seeded at a 
density of 50,000 cells/ml in RPMI medium containing 10% 
fetal calf serum. Drug solutions were immediately added in 
varying concentrations. After seven days, cells were counted 
using a Neubauer counting chamber. Cell numbers were 
counted 16 times and the results were averaged. The resulting 
growth curves represent the net outcome of cell proliferation 
and cell death. The substance concentration resulting in 50% 
growth inhibition (IC50 value) was calculated from the  
dose-response curves, assuming linearity of the curve in the 
proximity of the IC50. The following formula was used: 
 
a = concentration of the substance resulting in less than 50% 
growth inhibition 
b = concentration of the substance resulting in more than 
50% growth inhibition 
c = measured cell growth (% of control) at concentration b 
 
Figure 1.  Chemical structures of SM616 and GHP-AJM-3/23
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d = measured cell growth (% of control) at concentration a 
 
Calcein-AM Assay with Aherent PBCEC. Cells were  
isolated and cultivated in collagen-coated 96-well plates as 
described above. Medium was changed on day after prepara-
tion and from there on at every second day. Six days after  
isolation, medium was changed and the cells were held in me-
dium lacking horse serum. On the seventh day after prepara-
tion, the assay was performed, provided that a stable monolay-
er had developed. Substance stock solutions were prepared in 
DMSO. Dilutions were made in aqua bidest. assured that the 
final DMSO concentration on the cells did not exceed 1%. In 
the assay, medium was removed and cells were washed twice 
with Krebs-Ringer-buffer (KRB). The composition of KRB 
was: 142 mM NaCl, 3 mM KCl, 1.8 mM K2HPO4 × 3 H2O, 10 
mM HEPES, 4 mM D-Glucose, 1.3 mM MgCl2 × 6 H2O, 1.4 
mM CaCl2 × 2 H2O. Substance solutions in different concen-
trations were added and the plates were incubated for 15 min 
at 37 °C. An equal volume of 2 μM calcein-acetoxymethylester
(calcein-AM) was added (resulting in 1 μM calcein-AM-
solution in the assay) and incubated for 30 min at 37 °C. The 
layer was then washed twice with KRB (cooled down to 4 °C) 
to stop calcein-AM hydrolysis and remove extracellular calce-
in. For cell lysis, plates were incubated at 37 °C in 1% Tri-
tonX-100 for 20 min. Afterwards, fluorescence was measured 
with Fluoroskan Ascent plate reader (Labsystems, Waltham 
MA, USA) at 485 nm excitation and 520 nm emission. 
 
Calcein-AM Assay with CCRF-CEM and CEM/ADR5000
Leukemia Cells in Suspension. Cells were cultivated in 
RPMI 1640 medium as described above. Substance stock  
solutions were prepared in DMSO. Dilutions were made in 
aqua bidest. The final DMSO concentration on the cells did 
not exceed 1%. Cells were seeded at a density of 2.5 ×106 
cells/ml in RPMI 1640 medium. An aliquot of the substance 
solution was added and incubated at 37 °C for 15 min.  
Subsequently, the same volume of 4 μM Calcein-AM-solution 
was added, resulting in a final concentration of 1 μM Calcein-
AM solution. The suspension was incubated at 37 °C for 30 
min. To stop the reaction, the suspension was cooled to 4°C 
and cells were centrifuged at 500 × g for 5 min. The pellet was 
washed twice with 4 °C cold RPMI 1640 medium and was 
finally suspended therein. To each sample, propidium iodide 
was added to a final concentration of 0.5 μM. Afterwards, 
fluorescence was measured with FACSCalibur up to 20,000 
counts, according to the manufacturer’s instructions (Becton 
and Dickinson Biosciences, San José, USA). The excitating 
laser-light had a wavelength of 488 nm. Calcein was measured 
with FL1-channel, which measures light that passed through a 
530/30 bandpass filter. Propidium iodide was measured with 
FL3-channel, measuring light passing through a 650 nm 
longpass filter. Data was analysed using the CellQuest Pro 
software (Becton and Dickinson Biosciences, San José, USA). 
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